Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
about
sameAs
Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderThe interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersIs human cell therapy research caught in a mousetrap?Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationEx vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapyExtranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.Enhancing adoptive immunotherapy of cancer.Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer.Risk stratification in extranodal natural killer/T-cell lymphoma.Personalized cancer vaccines.Management of viral infections in solid organ transplant recipients.Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections.Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
P2860
Harvesting Cells for Experimental Cancer TreatmentsIntraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerAdministration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic CancerPhase I EGFR BATs in Newly Diagnosed GlioblastomaImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular MelanomaChemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic MelanomaAdoptive Cell Therapy Across Cancer DiagnosesHer2-BATS and Pembrolizumab in Metastatic Breast CancerBATs Treatment for Pancreatic Cancer, Phase Ib/IILymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic MelanomaChemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic MelanomaA Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and LymphomaAdoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid TumorsA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid TumorsStudy of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLMutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic CancerNon-Viral TCR Gene TherapyLymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
P921
Q26859114-1A877415-24E9-4A30-98FF-5A5A19E474C4Q34166602-E190E738-C3B9-42F2-A2DA-BBB521AB7CCBQ34556966-695EA22B-78EA-4CEF-8236-B6321173FCFEQ35005421-0C403C6A-8155-4AAE-8D46-28E0A572D31FQ35849338-4E8D768C-1A2E-4D3E-8069-D629B4B3B493Q37183682-383C804B-6829-4868-A951-C3FC66ED7193Q37626051-768C1274-41E5-44B7-96F9-E294D4841083Q37687429-C7CA49AE-AD56-4ADE-9A1A-B9EB6FAF1BE8Q37767556-B3A31A5F-46D8-476E-92F1-D667AA929227Q37773234-830CF415-AA46-4708-B6A9-E92CAA8EA64FQ37788238-B914C4A4-A675-42EC-87C6-1149F8259DA8Q37803417-6A1AE82D-8465-4D05-A2E2-F7AC3A482E3EQ37892559-7F43F1F1-1B71-4E37-8D7D-0FA3A38BD9F9Q38797555-624713D0-A213-4500-9D93-B3C43D75ED81Q41500928-760E5545-0D67-4297-806B-8970D848F7EEQ45324037-739FE0B7-254A-4323-8A1C-20FBE22B2280
P2860
Q64150629-28BB2C01-DE16-4BB9-AE07-928067738227Q64172784-CE14F120-65D8-490D-9FC6-8E608B384E39Q64172893-C901F1BF-6417-4EED-BEBC-EEDEC20C0020Q64184739-301C4F61-2CBF-407A-A9AF-38AE7C901A42Q64625938-F041BB49-AD69-4A35-9650-6EE00D4EA4A7Q64674476-15A33DA0-648C-48B8-946A-529A06F06793Q64790886-B7E2C60F-178B-425E-A22B-C8E3CB26C8D4Q64819391-10E7B54A-0524-4C50-9C1A-E99D26B27074Q64819581-9C814AE0-7DF2-4464-B70C-AC075F4CA14DQ65376899-277AF123-49EF-479F-B858-283C55B31FB3Q65391363-98816F01-8CAA-4522-BF61-F6DBBC161463Q66043841-E65E11B3-EBA7-47BD-BA7F-125CB1B467FBQ66063961-1755FF81-A856-42DD-B8EF-86509FFA5402Q66065271-9F4376E1-D610-4F40-8C24-DEBC05FE8235Q74132717-6432B20E-DEFF-4E8A-8169-1B50AFB14432Q74270693-CAA24B58-5D70-4765-92F0-325951BC9F7FQ74281340-8C1EE9B4-0C6C-45F1-94B7-3F2A1CFD484DQ76981977-CB20D670-0A61-44D7-89D9-6DE32B6C2E0B
P921
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
description
im September 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 September 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2008
@uk
name
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
@en
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
@nl
type
label
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
@en
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
@nl
prefLabel
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
@en
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
@nl
P2093
P2860
P50
P1476
Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
@en
P2093
Alberto Amadori
Anna Merlo
Riccardo Turrini
P2860
P304
P356
10.1517/14712598.8.9.1265
P407
P577
2008-09-01T00:00:00Z